Highlight
Tirzepatide, a dual GIP and GLP-1 receptor agonist, significantly reduced HbA1c and BMI in youth with type 2 diabetes compared to placebo over 30 weeks, with sustained benefits up to 52 weeks. The safety profile was consistent with previous adult data, primarily mild to moderate gastrointestinal adverse events.
